Alzheimer's drug Leqembi forecast to generate $12.9 billion in sales by 2028

6 April 2023

alzheimer-s-neurology-brain-dementia-big

Having received accelerated approval from US Food and Drug Administration (FDA) in January this year for their Alzheimer’s disease drug Leqembi (lecanemab), Japan’s Eisai (TYO: 4523) and US biotech Biogen (Nasdaq: BIIB) are now awaiting authorizations in the important markets of the European Union and Japan to solidify the drug’s position as the top-selling drug for Alzheimer's in the upcoming years.

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9 billion between 2023 and 2028, according to data and analytics company GlobalData.

The FDA decision on Leqembi was based on data from a Phase II clinical trial named Athena AD. The results of the trial showed that treatment led to a significant reduction in the amount of amyloid beta plaques in the brain and demonstrated a statistically significant reduction in cognitive decline in patients treated with Leqembi compared to those who received a placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK